A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy
Abstract
:1. Introduction
2. Results
2.1. Overexpression of IL-1R1 Correlates with Reduced Patient Sensitivity to Cetuximab
2.2. A Recombinant Decoy Containing IL-1R1 Inhibits Growth In Vitro
2.3. TRAP IL-1 Clones Display Decreased Cancer Cell Spheroidogenesis in 3D
2.4. IL-1 Pathway Inhibition Impairs MAPK Signaling
2.5. IL-1 Receptor Abundance Predicts Relapse-Free Survival in CRC Patients
3. Discussion
4. Materials and Methods
4.1. Cell Culture
4.2. Colony Forming Assay
4.3. Spheroid Assay
4.4. Confocal Microscopy
4.5. Immunoblotting
4.6. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Yarden, Y.; Pines, G. The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 2012, 12, 553–563. [Google Scholar] [CrossRef] [PubMed]
- Schäfer, B.; Gschwind, A.; Ullrich, A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 2004, 23, 991–999. [Google Scholar] [CrossRef] [PubMed]
- Carpenter, G. EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists. Sci. STKE 2000, 2000, pe1. [Google Scholar] [CrossRef] [PubMed]
- Daub, H.; Wallasch, C.; Lankenau, A.; Herrlich, A.; Ullrich, A.; Barnard, E.; Burnstock, G.; Webb, T.; Bonfini, L.; Migliaccio, E.; et al. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 1997, 16, 7032–7044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grivennikov, S.I.; Greten, F.R.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef] [PubMed]
- Ramnarain, D.B.; Paulmurugan, R.; Park, S.; Mickey, B.E.; Asaithamby, A.; Saha, D.; Kelliher, M.A.; Mukhopadhyay, P.; Banani, F.; Madden, C.J.; et al. RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR. Cell Death Differ. 2008, 15, 344–353. [Google Scholar] [CrossRef] [PubMed]
- D’Uva, G.; Lauriola, M. Towards the emerging crosstalk: ERBB family and steroid hormones. Semin. Cell Dev. Biol. 2016, 50, 143–152. [Google Scholar] [CrossRef] [PubMed]
- Lauriola, M.; Enuka, Y.; Zeisel, A.; D’Uva, G.; Roth, L.; Sharon-Sevilla, M.; Lindzen, M.; Sharma, K.; Nevo, N.; Feldman, M.; et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat. Commun. 2014, 5, 5073. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Webster, J.C.; Cidlowski, J.A. Mechanisms of glucocorticoid-receptor-mediated repression of gene expression. Trends Endocrinol. Metab. 1999, 10, 396–402. [Google Scholar] [CrossRef]
- Petrovsky, N.; McNair, P.; Harrison, L.C. Diurnal rhythms of pro-inflammatory cytokines: Regulation by plasma cortisol and therapeutic implications. Cytokine 1998, 10, 307–312. [Google Scholar] [CrossRef] [PubMed]
- De Roock, W.; Claes, B.; Bernasconi, D.; De Schutter, J.; Biesmans, B.; Fountzilas, G.; Kalogeras, K.T.; Kotoula, V.; Papamichael, D.; Laurent-Puig, P.; et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 2010, 11, 753–762. [Google Scholar] [CrossRef]
- Bardelli, A.; Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28, 1254–1261. [Google Scholar] [CrossRef] [PubMed]
- Chong, C.R.; Jänne, P.A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 2013, 19, 1389–1400. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G.; et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012. [Google Scholar] [CrossRef] [PubMed]
- Medico, E.; Russo, M.; Picco, G.; Cancelliere, C.; Valtorta, E.; Corti, G.; Buscarino, M.; Isella, C.; Lamba, S.; Martinoglio, B.; et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 2015, 6, 7002. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trusolino, L.; Bertotti, A. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: Six degrees of separation. Cancer Discov. 2012, 2, 876–880. [Google Scholar] [CrossRef] [PubMed]
- Engelman, J.A.; Jänne, P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 2008, 14, 2895–2899. [Google Scholar] [CrossRef] [PubMed]
- Bivona, T.G.; Doebele, R.C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 2016, 22, 472–478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Misale, S.; Di Nicolantonio, F.; Sartore-Bianchi, A.; Siena, S.; Bardelli, A. Resistance to Anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov. 2014, 4, 1269–1280. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.J.; Zhuang, G.; Cao, Y.; Du, P.; Kim, H.J.; Settleman, J. Drug resistance via feedback activation of stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26, 207–221. [Google Scholar] [CrossRef] [PubMed]
- Blakely, C.M.; Pazarentzos, E.; Olivas, V.; Asthana, S.; Yan, J.J.; Tan, I.; Hrustanovic, G.; Chan, E.; Lin, L.; Neel, D.S.; et al. NF-κB-Activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015, 11, 98–110. [Google Scholar] [CrossRef] [PubMed]
- Meads, M.B.; Gatenby, R.A.; Dalton, W.S. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9, 665–674. [Google Scholar] [CrossRef] [PubMed]
- Apte, R.N.; Voronov, E. Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. J. Leukoc. Biol. 2017, 102, 293–306. [Google Scholar] [CrossRef] [PubMed]
- Todoric, J.; Antonucci, L.; Karin, M. Targeting inflammation in cancer prevention and therapy. Cancer Prev. Res. 2016, 9, 895–905. [Google Scholar] [CrossRef] [PubMed]
- Stanam, A.; Gibson-Corley, K.N.; Love-Homan, L.; Ihejirika, N.; Simons, A.L.; Stanam, A.; Gibson-Corley, K.N.; Love-Homan, L.; Ihejirika, N.; Simons, A.L.; et al. Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma. Oncotarget 2016, 7, 76087–76100. [Google Scholar] [CrossRef] [PubMed]
- Gelfo, V.; Rodia, M.T.; Pucci, M.; Dall’Ora, M.; Santi, S.; Solmi, R.; Roth, L.; Lindzen, M.; Bonafè, M.; Bertotti, A.; et al. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget 2016. [Google Scholar] [CrossRef] [PubMed]
- Vallböhmer, D.; Zhang, W.; Gordon, M.; Yang, D.Y.; Yun, J.; Press, O.A.; Rhodes, K.E.; Sherrod, A.E.; Iqbal, S.; Danenberg, K.D.; et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 2005, 23, 3536–3544. [Google Scholar] [CrossRef] [PubMed]
- Khambata-Ford, S.; Garrett, C.R.; Meropol, N.J.; Basik, M.; Harbison, C.T.; Wu, S.; Wong, T.W.; Huang, X.; Takimoto, C.H.; Godwin, A.K.; et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 2007, 25, 3230–3237. [Google Scholar] [CrossRef] [PubMed]
- Lindzen, M.; Carvalho, S.; Starr, A.; Ben-Chetrit, N.; Pradeep, C.R.; Köstler, W.J.; Rabinkov, A.; Lavi, S.; Bacus, S.S.; Yarden, Y. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 2012, 31, 3505–3515. [Google Scholar] [CrossRef] [PubMed]
- Jaffe, A.B.; Kaji, N.; Durgan, J.; Hall, A. Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis. J. Cell Biol. 2008, 183, 625–633. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, C.; Singh, B.; Graves-Deal, R.; Ma, H.; Starchenko, A.; Fry, W.H.; Lu, Y.; Wang, Y.; Bogatcheva, G.; Khan, M.P.; et al. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proc. Natl. Acad. Sci. USA 2017, 114, E2852–E2861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zwang, Y.; Yarden, Y. p38 MAP kinase mediates stress-induced internalization of EGFR: Implications for cancer chemotherapy. EMBO J. 2006, 25, 4195–4206. [Google Scholar] [CrossRef] [PubMed]
- Garlanda, C.; Dinarello, C.A.; Mantovani, A. The Interleukin-1 Family: Back to the Future. Immunity 2013, 39, 1003–1018. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weber, A.; Wasiliew, P.; Kracht, M. Interleukin-1 (IL-1) Pathway. Sci. Signal. 2010, 3, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Sztupinszki, Z.; Gyorffy, B. Colon cancer subtypes: Concordance, effect on survival and selection of the most representative preclinical models. Sci. Rep. 2016, 6. [Google Scholar] [CrossRef] [PubMed]
- Guinney, J.; Dienstmann, R.; Wang, X.; de Reyniès, A.; Schlicker, A.; Soneson, C.; Marisa, L.; Roepman, P.; Nyamundanda, G.; Angelino, P.; et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015, 21, 1350–1356. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Sousa E Melo, F.; Wang, X.; Jansen, M.; Fessler, E.; Trinh, A.; de Rooij, L.P.M.H.; de Jong, J.H.; de Boer, O.J.; van Leersum, R.; Bijlsma, M.F.; et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 2013, 19, 614–618. [Google Scholar] [CrossRef] [PubMed]
- Amit, I.; Wides, R.; Yarden, Y. Evolvable signaling networks of receptor tyrosine kinases: Relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 2007, 3. [Google Scholar] [CrossRef] [PubMed]
- Luke, J.J.; Flaherty, K.T.; Ribas, A.; Long, G.V. Targeted agents and immunotherapies: Optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 2017, 14, 463–482. [Google Scholar] [CrossRef] [PubMed]
- Mlecnik, B.; Bindea, G.; Kirilovsky, A.; Angell, H.K.; Obenauf, A.C.; Tosolini, M.; Church, S.E.; Maby, P.; Vasaturo, A.; Angelova, M.; et al. The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci. Transl. Med. 2016, 8, 327ra26. [Google Scholar] [CrossRef] [PubMed]
- Kirilovsky, A.; Marliot, F.; El Sissy, C.; Haicheur, N.; Galon, J.; Pagès, F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int. Immunol. 2016, 28, 373–382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Proctor, M.J.; Morrison, D.S.; Talwar, D.; Balmer, S.M.; Fletcher, C.D.; O’reilly, D.S.J.; Foulis, A.K.; Horgan, P.G.; Mcmillan, D.C. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur. J. Cancer 2011, 47, 2633–2641. [Google Scholar] [CrossRef] [PubMed]
- Song, W.; Wang, K.; Zhang, R.-J.; Zou, S.-B. Prognostic value of the lymphocyte monocyte ratio in patients with colorectal cancer: A meta-analysis. Medicine 2016, 95, e5540. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Mantovani, A.; Allavena, P.; Allavena, P.; Sica, A.; Sica, A.; Balkwill, F.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Netea, M.G.; Nold-Petry, C.A.; Nold, M.F.; Joosten, L.A.B.; Opitz, B.; Van Der Meer, J.H.M.; Van De Veerdonk, F.L.; Ferwerda, G.; Heinhuis, B.; Devesa, I.; et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009, 113, 2324–2335. [Google Scholar] [CrossRef] [PubMed]
- De Palma, M.; Lewis, C.E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013, 23, 277–286. [Google Scholar] [CrossRef] [PubMed]
- Lee, M.S.; Vincent, B.G.; McRee, A.J.; Sanoff, H.K. Association between cetuximab response and differential immunologic gene expression signatures in colorectal cancer metastases. J. Clin. Oncol. 2016, 34 (Suppl. 4), 558. [Google Scholar] [CrossRef]
- Andreu, P.; Johansson, M.; Affara, N.I.; Pucci, F.; Tan, T.; Junankar, S.; Korets, L.; Lam, J.; Tawfik, D.; DeNardo, D.G.; et al. FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis. Cancer Cell 2010, 17, 121–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pander, J.; Heusinkveld, M.; Van Der Straaten, T.; Jordanova, E.S.; Baak-Pablo, R.; Gelderblom, H.; Morreau, H.; Van Der Burg, S.H.; Guchelaar, H.J.; Van Hall, T. Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin. Cancer Res. 2011, 17, 5668–5673. [Google Scholar] [CrossRef] [PubMed]
- Voronov, E.; Apte, R.N. IL-1 in Colon Inflammation, Colon Carcinogenesis and Invasiveness of Colon Cancer. Cancer Microenviron. 2015, 8, 187–200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garborg, K.; Holme, Ø.; Løberg, M.; Kalager, M.; Adami, H.O.; Bretthauer, M. Current status of screening for colorectal cancer. Ann. Oncol. 2013, 24, 1963–1972. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaler, P.; Augenlicht, L.; Klampfer, L. Macrophage-derived IL-1β stimulates Wnt signaling and growth of colon cancer cells: A crosstalk interrupted by vitamin D3. Oncogene 2009, 28, 3892–3902. [Google Scholar] [CrossRef] [PubMed]
- Apte, R.N.; Voronov, E. Interleukin-1—A major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002, 12, 277–290. [Google Scholar] [CrossRef]
- Dienstmann, R.; Vermeulen, L.; Guinney, J.; Kopetz, S.; Tejpar, S.; Tabernero, J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 2017. [Google Scholar] [CrossRef]
- Fessler, E.; Medema, J.P. Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. Trends in Cancer 2016, 2, 505–518. [Google Scholar] [CrossRef] [PubMed]
- Janes, K.A.; Gaudet, S.; Albeck, J.G.; Nielsen, U.B.; Lauffenburger, D.A.; Sorger, P.K. The Response of Human Epithelial Cells to TNF Involves an Inducible Autocrine Cascade. Cell 2006, 124, 1225–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Avraham, R.; Yarden, Y. Feedback regulation of EGFR signalling: Decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12, 104–117. [Google Scholar] [CrossRef] [PubMed]
- Dinarello, C.A. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010, 29, 317–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, C.; Ma, H.; Wang, Y.; Cao, Z.; Graves-Deal, R.; Powell, A.E.; Starchenko, A.; Ayers, G.D.; Washington, M.K.; Kamath, V.; et al. Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. J. Clin. Investig. 2014, 124, 2172–2187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Everett, B.M.; Libby, P.; Glynn, R.J.; Ridker, P.; Lorenzatti, A.; Krum, H.; Varigos, J.; et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017, 390, 1833–1842. [Google Scholar] [CrossRef]
AREG vs. IL-1R1, p-Value | EREG vs. IL-1R1, p-Value | |
---|---|---|
PD | −0.50 (0.00057) | −0.44 (0.003308) |
SD | −0.55 (0.01881) | −0.47 (−0.04905) |
OR | −0.05 | −0.08 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gelfo, V.; Mazzeschi, M.; Grilli, G.; Lindzen, M.; Santi, S.; D’Uva, G.; Győrffy, B.; Ardizzoni, A.; Yarden, Y.; Lauriola, M. A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers 2018, 10, 355. https://doi.org/10.3390/cancers10100355
Gelfo V, Mazzeschi M, Grilli G, Lindzen M, Santi S, D’Uva G, Győrffy B, Ardizzoni A, Yarden Y, Lauriola M. A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers. 2018; 10(10):355. https://doi.org/10.3390/cancers10100355
Chicago/Turabian StyleGelfo, Valerio, Martina Mazzeschi, Giada Grilli, Moshit Lindzen, Spartaco Santi, Gabriele D’Uva, Balázs Győrffy, Andrea Ardizzoni, Yosef Yarden, and Mattia Lauriola. 2018. "A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy" Cancers 10, no. 10: 355. https://doi.org/10.3390/cancers10100355